Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY 1,458.00
+12.00 (0.83%)
Mar 12, 2025, 3:30 PM JST
Astellas Pharma Employees
Astellas Pharma had 14,754 employees as of March 31, 2024. The number of employees increased by 270 or 1.86% compared to the previous year.
Employees
14,754
Change (1Y)
270
Growth (1Y)
1.86%
Revenue / Employee
126.58M JPY
Profits / Employee
-3.89M JPY
Market Cap
2,609.98B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 7,604 |
| Takeda Pharmaceutical Company | 49,281 |
| Daiichi Sankyo Company | 18,726 |
| HOYA Corporation | 35,702 |
| Otsuka Holdings | 35,338 |
| Olympus | 28,838 |
| Shionogi & | 4,959 |
| Sysmex | 10,042 |
Astellas Pharma News
- 6 days ago - Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - PRNewsWire
- 13 days ago - Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize - PRNewsWire
- 27 days ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire
- 4 weeks ago - Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
- 4 weeks ago - Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Benzinga
- 4 weeks ago - Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan - PRNewsWire